Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins

Key Points

• The aim is to evaluate the pentapharmacological effects of otamixaban on various lung cancer-related proteins.
• Correction of previously published findings on otamixaban therapy.
• Focus on its interaction with CDK2, transferase, oxidoreductase, and signalling proteins.
• Findings detail otamixaban's potential efficacy against lung cancer pathways.